MONAS
FINANCIAL
Home
About
Research
Data
Pricing
Team
News
Analysis
Press
Contact
Legal
← News
Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $480
Analyst Ratings
AMGN
Oct 23
AI-curated analysis for informational purposes only — not investment advice.
Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $480
Read the full story at benzinga.com →